Arbutus Biopharma Corporation (ABUS)

[mick]

$8.00 RATING, Chardan Capital Remains a Buy on Arbutus Biopharma (ABUS)
Christine Brown- November 16, 2020, 9:45 PM EDTSHARE ON:
Chardan Capital Remains a Buy on Arbutus Biopharma (ABUS)In a report released yesterday, Keay Nakae from Chardan Capital reiterated a Buy rating on Arbutus Biopharma (ABUS), with a price target of $5.00. The company’s shares closed last Monday at $3.63.

According to TipRanks.com, Nakae is a 4-star analyst with an average return of 6.9% and a 46.3% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Lineage Cell Therapeutics, and Emergent Biosolutions.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arbutus Biopharma with a $6.50 average price target, a 63.3% upside from current levels. In a report issued on November 6, B.Riley Financial also reiterated a Buy rating on the stock with a $8.00 price target.